QUININE ASCORBATE

US Previously Marketed

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C20H24N2O2.2C6H8O6
Molecular Weight	676.665
Optical Activity	UNSPECIFIED
Defined Stereocenters	8 / 8
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.OC[C@H](O)[C@H]2OC(=O)C(O)=C2O.COC3=CC4=C(C=CN=C4C=C3)[C@@H](O)[C@@H]5C[C@@H]6CCN5C[C@@H]6C=C

InChI

InChIKey=CJHQUYQRCLIWSW-JPGAVJPLSA-N

InChI=1S/C20H24N2O2.2C6H8O6/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18;2*7-1-2(8)5-3(9)4(10)6(11)12-5/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3;2*2,5,7-10H,1H2/t13-,14-,19-,20+;2*2-,5+/m000/s1

HIDE SMILES / InChI

Molecular Formula	C20H24N2O2
Molecular Weight	324.4168
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C6H8O6
Molecular Weight	176.1241
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=310&showFR=1 | https://www.ncbi.nlm.nih.gov/pubmed/8008450 | https://www.drugs.com/ppa/quinine.html

Quinine ascorbate is a salt of antimalarial drug quinine and ascorbic acid (vitamin C). Ascorbate reduces the potency of quinolone-containing anti-malarial drugs. Quinine ascorbate was marketed as a component of over-the-counter smoking deterrent products but was not recognized as safe by the FDA regulation in 1993.

Approval Year

C_max

Value	Dose	Analyte	Population
3.2 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021799lbl.pdf	8.7 mg/kg single, oral dose: 8.7 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	QUININE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
8.4 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021799lbl.pdf	10 mg/kg single, oral dose: 10 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	QUININE plasma	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
9.7 μg/mL EXPERIMENT https://www.sciencedirect.com/science/article/abs/pii/S0022347685806922	300 mg/m² single, intravenous dose: 300 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:	QUININE serum	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN
10.6 μg/mL EXPERIMENT https://www.sciencedirect.com/science/article/abs/pii/S0022347685806922	300 mg/m² single, intramuscular dose: 300 mg/m² route of administration: Intramuscular experiment type: SINGLE co-administered:	QUININE serum	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN
10.3 μg/mL EXPERIMENT https://www.sciencedirect.com/science/article/abs/pii/S0022347685806922	300 mg/m² single, intragastric dose: 300 mg/m² route of administration: Intragastric experiment type: SINGLE co-administered:	QUININE serum	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN
11.3 μg/mL EXPERIMENT https://www.sciencedirect.com/science/article/abs/pii/S0022347685806922	300 mg/m² 2 times / day multiple, intramuscular dose: 300 mg/m² route of administration: Intramuscular experiment type: MULTIPLE co-administered:	QUININE serum	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
28 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021799lbl.pdf	8.7 mg/kg single, oral dose: 8.7 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	QUININE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
73 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021799lbl.pdf	10 mg/kg single, oral dose: 10 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	QUININE plasma	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
90.5 μg × h/mL EXPERIMENT https://www.sciencedirect.com/science/article/abs/pii/S0022347685806922	300 mg/m² single, intravenous dose: 300 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:	QUININE serum	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN
87.2 μg × h/mL EXPERIMENT https://www.sciencedirect.com/science/article/abs/pii/S0022347685806922	300 mg/m² single, intramuscular dose: 300 mg/m² route of administration: Intramuscular experiment type: SINGLE co-administered:	QUININE serum	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN
95.4 μg × h/mL EXPERIMENT https://www.sciencedirect.com/science/article/abs/pii/S0022347685806922	300 mg/m² single, intragastric dose: 300 mg/m² route of administration: Intragastric experiment type: SINGLE co-administered:	QUININE serum	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
12.5 h EXPERIMENT https://www.sciencedirect.com/science/article/abs/pii/S0022347685806922	300 mg/m² single, intravenous dose: 300 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:	QUININE serum	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN
8.4 h EXPERIMENT https://www.sciencedirect.com/science/article/abs/pii/S0022347685806922	300 mg/m² single, intramuscular dose: 300 mg/m² route of administration: Intramuscular experiment type: SINGLE co-administered:	QUININE serum	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN
13.1 h EXPERIMENT https://www.sciencedirect.com/science/article/abs/pii/S0022347685806922	300 mg/m² single, intragastric dose: 300 mg/m² route of administration: Intragastric experiment type: SINGLE co-administered:	QUININE serum	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN
9.8 h EXPERIMENT https://www.sciencedirect.com/science/article/abs/pii/S0022347685806922	300 mg/m² 2 times / day multiple, intramuscular dose: 300 mg/m² route of administration: Intramuscular experiment type: MULTIPLE co-administered:	QUININE serum	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inhibitor 2252 inducer 1087	substrate 1193	substrate 1388 inhibitor 2507

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OCTN1 32 OCT3 159 OCTN2 71 OCT2 779 OATP1B1 1079 OATP1B3 961 OATP2B1 157 OCT1 620 BSEP 550 MRP2 499 MRP3 246 MRP4 290 P-gp 1741 OATP1A2 43 CYP2C8 1057 CYP2C19 2057 CYP1A1 132	CYP2C19 1119 CYP2E1 729 CYP3A7 109 P-gp 2052 CYP3A5 446 CYP1A2 1197 CYP2C8 810 OCT2 434 OCT1 393	CYP1A2 832

Drug as perpetrator

Target	Modality	Activity
BSEP 554	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw2MDIwIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE3MCJ9fQ%3D%3D	no [IC50 >133 uM]
MRP2 625	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1NzQ4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE3MCJ9fQ%3D%3D	no [IC50 >133 uM]
MRP3 326	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1OTE4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE3MCJ9fQ%3D%3D	no [IC50 >133 uM]
MRP4 345	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTI4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE3MCJ9fQ%3D%3D	no [IC50 >133 uM]
OATP1B3 970	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/22541068/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTIxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE3MCJ9fQ%3D%3D	no [Inhibition 20 uM]
OATP2B1 162	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/22541068/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTI0IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE3MCJ9fQ%3D%3D	no [Inhibition 20 uM]
OCTN1 32	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyMDczNjY4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE3MCJ9fQ%3D%3D	weak
CYP2D6 2546	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/16610785/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTcwIn19	yes [IC50 1.8 uM]
P-gp 1932	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/11716514/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw0MzAyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE3MCJ9fQ%3D%3D	yes [IC50 22.6 uM]
OCT1 656	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/18788725/,https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1Njg1IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE3MCJ9fQ%3D%3D	yes [IC50 51.6 uM]
OATP1B1 1095	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/22541068/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNjk3NjY4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE3MCJ9fQ%3D%3D	yes [Inhibition 20 uM]
CYP2C8 1117	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/11136296/, https://go.drugbank.com/drugs/DB00468	yes [Inhibition 80 uM]
OCT2 782	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE3MCJ9fQ%3D%3D	yes [Ki 3.4 uM]
CYP1A1 272	inhibitor 4027 Sources: https://go.drugbank.com/drugs/DB00468	yes
CYP1A2 2333	inducer 1966 Sources: https://go.drugbank.com/drugs/DB00468	yes
CYP2C19 2141	inhibitor 4027 Sources: https://go.drugbank.com/drugs/DB00468	yes
CYP3A4 2633	inducer 1966 Sources: https://go.drugbank.com/drugs/DB00468	yes
CYP3A4 2633	inhibitor 4027 Sources: https://go.drugbank.com/drugs/DB00468	yes
OATP1A2 43	inhibitor 4027 Sources: https://go.drugbank.com/drugs/DB00468	yes
OCT3 161	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/28811134/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyMDczNjczIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE3MCJ9fQ%3D%3D	yes
OCTN2 71	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/10525100/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyMDczNjkzIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE3MCJ9fQ%3D%3D	yes

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP1A2 1197	substrate 4014 Sources: https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/632/original/FDA_label_Quinine.pdf?1537805198	likely
CYP2C19 1119	substrate 4014 Sources: https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/632/original/FDA_label_Quinine.pdf?1537805198	likely
CYP2C8 810	substrate 4014 Sources: https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/632/original/FDA_label_Quinine.pdf?1537805198	likely
CYP2C9 1193	substrate 4014 Sources: https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/632/original/FDA_label_Quinine.pdf?1537805198	likely
CYP2E1 729	substrate 4014 Sources: https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/632/original/FDA_label_Quinine.pdf?1537805198	likely
P-gp 2052	substrate 4014 Sources: https://www.genome.jp/kegg/drug/br08309.html	yes [Km 10 uM]
OCT2 434	substrate 4014 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE3MCJ9fQ%3D%3D	yes [Km 2.6 uM]
CYP2D6 1388	substrate 4014 Sources: https://go.drugbank.com/drugs/DB00468	yes
CYP3A5 446	substrate 4014 Sources: https://go.drugbank.com/drugs/DB00468	yes
CYP3A7 109	substrate 4014 Sources: https://go.drugbank.com/drugs/DB00468	yes
OCT1 393	substrate 4014 Sources: https://go.drugbank.com/drugs/DB00468	yes
CYP3A4 1946	substrate 4014 Sources: https://www.genome.jp/kegg/drug/br08309.html, https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021799s008lbl.pdf	yes	yes (co-administration study) Comment: Coadministration of Ketoconazole increased Quinine AUC by 45% and decreased a mean oral clearance of Quinine by 31%. Sources: https://www.genome.jp/kegg/drug/br08309.html, https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021799s008lbl.pdf

Sourcing

Vendor/Aggregator	ID	URL
ChEMBL	CHEMBL3707332
ChemIDplus	146407	https://chem.nlm.nih.gov/chemidplus/id/0000146407
PubChem	56840788	https://pubchem.ncbi.nlm.nih.gov/compound/56840788
Wikidata	Q27282158

Substance Class	Chemical Created by `admin` on `Mon Mar 31 19:20:33 GMT 2025` Edited by `admin` on `Mon Mar 31 19:20:33 GMT 2025`
Record UNII	KAU4V10S2I
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

L-ASCORBIC ACID, COMPOUND WITH (8.ALPHA.,9R)-6'-METHOXYCINCHONAN-9-OL (2:1)

Preferred Name

English

QUININE ASCORBATE

Official Name

English

QUININE ASCORBATE [MART.]

Common Name

English

L-ASCORBIC ACID, COMPOUND WITH QUININE (2:1)

Common Name

English

QUININE ASCORBATE [USAN]

Common Name

English

Classification Tree Code System Code

CFR

21 CFR 310.547